Yohannes Ghebre (Baylor College of Medicine, Houston, TX, US) discusses the rationale and clinical evidence to date for using proton pump inhibitors (PPIs) to treat idiopathic pulmonary fibrosis (IPF).
1. What are the limitations of the currently approved drugs, pirfenidone and nintedanib, in idiopathic pulmonary fibrosis (IPF)? (0:11)
2. What is the rationale for using proton pump inhibitors (PPIs) to treat IPF? (1:08)
3. What clinical evidence exists for the use of PPIs in IPF? (2:06)
4. What (if any) are the potential safety issues in using PPIs to treat patients with IPF? (2:55)
5. What further studies are needed? (3:26)
Speaker disclosure: Yohannes Ghebre is an inventor on a patent, owned by Stanford University, that protects the use of proton pump inhibitors (PPIs) for the treatment of idiopathic pulmonary fibrosis (IPF).
Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.
Share this Video
Related Videos In Interstitial Lung Disease
Elisabeth Bendstrup, ERS 2021: Challenges and Advances in ILD
We were delighted to talk with Professor Elisabeth Bendstrup (Aarhus University Hospital, Denmark) around the barriers and latest advances in treating interstitial lung disease. Questions What are the barriers to the early diagnosis of interstitial lung disease (ILD)? (0:18) What are the hot topics and latest research you are looking forward to exploring in ILD […]
Elisabeth Bendstrup, ERS 2021: The STARLINER Study
Professor Elisabeth Bendstrup (Aarhus University Hospital, Denmark) spoke with touchRESPIRATORY around the STARLINER study, assessing disease behaviour in ILD and the challenges associated with home-based assessments. The abstract ‘STARLINER study, disease behaviour assessed by a wide range of parameters including patient-reported outcomes (PRO) results.’ (Presentation ID: 1207) was presented at ERS International Congress 2021, 5-8 […]
Lauren Troy, ERS 2019 – Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis
We met with Lauren Troy, from Royal Prince Alfred Hospital, Sydney, Australia at ERS 2019 in Madrid to discuss result of the COLDICE study into transbronchial lung cryobiopsy for interstitial lung disease diagnosis. Questions 1. In what clinical situation is a lung biopsy required to confirm a diagnosis of interstitial lung disease? (0:05) 2. What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!